CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, cilt.17, sa.12, ss.804-811, 2017 (SCI-Expanded)
We retrospectively evaluated 90 patients with chronic myeloid leukemia receiving either upfront original imatinib (Ol) or generic imatinib (Gl) for the effect of the early molecular response on the long-term outcome. We demonstrated that achieving an optimal response at 3 and 6 months in patients receiving either first-line Gl or Ol was clearly associated with greater response and event-free survival rates.